 |
Gregory MacLennan, M.D.ProfessorMailing Address: email: Gregory.MacLennan@UHhospitals.org |
Biography
Dr. Gregory MacLennan earned his M.D. degree from the University of Manitoba, Canada, in 1971. He spent
six years training in General Surgery and Urology at Manitoba Affiliated Teaching Hospitals, and followed
this with a fellowship in Urodynamics at St. Peter’s Hospitals, London, England. From 1978 until 1989,
Dr. MacLennan practiced Urology in Grand Forks, N.D. and progressed from Clinical Instructor to
Associate Professor of Surgery at the University of North Dakota School of Medicine. In 1989, he returned
to Manitoba Affiliated Teaching Hospitals and spent 5 years in Residency and fellowship training in
Anatomic Pathology and Cytopathology. In 1994 began a Fellowship in Surgical and Genitourinary Pathology
at Mayo Clinic, Rochester, MN. Following his Fellowship, he joined the staff of the Department of Pathology
at CWRU in 1995. Dr. MacLennan is Board certified in both Urology and Anatomic Pathology in both Canada and
the United States. Additionally, he is Board certified in Cytopathology. Currently, Dr. MacLennan is
Director of the Human Tissue Procurement Facility at University Hospitals of Cleveland, Director of the
Tissue Procurement and Histology Core of the Ireland Cancer Center, and Director of Surgical Pathology in
the Department of Pathology. He is Professor of Pathology, Urology, and Oncology at Case Western Reserve
School of Medicine.
Research
Dr. MacLennan has a particular interest in genitourinary pathology. Much of his time is committed to
diagnostic surgical pathology and cytopathology. His research has been predominantly clinically oriented,
but has also involved collaborations with basic scientists.
Publications
Cheng L, Bishop E, Zhou H, MacLennan GT, Lopez-Beltran A, Zhang S, Badve S, Baldridge LA, Montironi
R: Lymphatic vessel density in radical prostatectomy specimens. Hum Pathol 39: 610-615, 2008.
Marks RA, Zhang S, Montironi R, McCarthy RP, MacLennan GT, Lopez-Beltran A, Jiang Z, Zhou H, Zheng S, Davidson DD, Baldridge LA, Cheng L: Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. The Prostate 68: 919-923, 2008.
Al-Khwawaja M, Tan PH, MacLennan GT, Lopez-Beltran A, Montironi R, Cheng L: Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. Hum Pathol 39: 954-959, 2008.
Gobbo S, Eble JN, Grignon DJ, Martignoni G, MacLennan GT, Shah RB, Zhang S, Brunelli M, Cheng L. Clear- cell papillary renal cell carcinoma: a distinct histopathological and molecular genetic entity. Am J Surg Pathol 32: 1239-1245, 2008.
Cheng L, MacLennan GT, Abdul-Karim FW, Lopez-Beltran A, Montironi R: Eosinophilic metaplasia of the prostate: a newly described lesion distinct from other eosinophilic changes in the prostatic epithelium. Anal Quan Cytol Histol 30: 226-230, 2008.
Hossain D, Meiers I, Qian J, MacLennan GT, Bostwick DG. Prostatic leiomyoma with atypia: follow-up study of 10 cases. Ann Diagn Pathol 12: 328-332, 2008.
Hossain D, Meiers I, Qian J, MacLennan GT, Bostwick DG. Prostatic stromal hyperplasia with atypia: follow-up of 18 cases. Arch Pathol Lab Med 132: 1729-1733, 2008.
Sanborn S, MacLennan GT, Cooney M, Zhou M, Ponsky L. High grade transitional cell carcinoma and melanosis of the urinary bladder: case report and review of the literature. Urology, 2009 Apr;73(4):928.e13-5. Epub 2008 Dec 4.
Vykhovanets EV, Shukla S, MacLennan GT, Resnick MI, Carlsen H, Blomhoff R, Gupta S. Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1 beta. Prostate 68: 34-41, 2008.